Zobrazeno 1 - 10
of 11
pro vyhledávání: '"502"'
Autor:
Sanjay Goel, Devika Rao, Seda Serra Tolu, Ana Acuna-Villaorduna, Michael Lyudmer, Andreas Kaubisch, Tarek N. Elrafei, Jennifer W. Chuy, Riya Jayesh Patel, Adel Chergui
Publikováno v:
Journal of Clinical Oncology. 39:141-141
141 Background: Differences in incidence, clinical features, and survival between early-onset (EO) and standard-onset (SO) colorectal cancer (CRC) are well-established. Factors associated with longer survival have not been reported. We aim to determi
Autor:
Mary Beth Landrum, Jessica Cleveland, Gabriel A. Brooks, Alexi A. Wright, José R. Zubizarreta, Nancy L. Keating
Publikováno v:
Journal of Clinical Oncology. 38:2073-2073
2073 Background: Alternative payment models for oncology seek to improve quality and reduce spending. Yet the ability to measure high-quality care across oncology practices remains uncertain. We characterized quality of care for oncology practices us
Publikováno v:
Journal of Clinical Oncology. 37:502-502
502 Background: Right-sided colon cancers (RCC) are defined up to the splenic flexure where as left-sided colon cancers (LCC) involve the descending, sigmoid, and rectosigmoid regions. The landmark CALGB/SWOG 80405 study concluded that sidedness was
Autor:
Bernhard C. Pestalozzi, Tae Won Kim, Mark P Saunders, Brigitte M. Van Eyll, Krassimir D. Koynov, Paulo M. Hoff, Tamás Pintér, Andreas Hochhaus, Niall C. Tebbutt, Ying Cheng, Jin Li, Laura Pike, G. Kurteva, Jane Robertson, Anitra Fielding
Publikováno v:
Journal of Clinical Oncology. 30:3596-3603
Purpose Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signaling with activity against all three VEGF receptors. HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemothera
Publikováno v:
Journal of Clinical Oncology. 35:742-742
742 Background: The anatomical side of the colon where a tumor arises has been shown to be prognostic in patients treated with first-line therapy; patients with tumors that arise from the left side of the colon have significantly longer survival comp
Autor:
Mitsuyoshi Ota, Masashi Momiyama, Yasushi Ichikawa, Itaru Endo, Jun Watanabe, Atsushi Ishibe, Hirokazu Suwa, Chikara Kunisaki
Publikováno v:
Journal of Clinical Oncology. 34:502-502
502 Background: Neoadjuvant chemotherapy for locally advanced rectal cancer is required to achieve tumor reduction when skipping routine use of preoperative radiation therapy. It is known that EGFR inhibitor has impact on early tumor shrinkage in met
Autor:
Aravind Shivasami, Joseph W. Wrin, David Cunningham, Georgia Arentz, Amanda R. Townsend, Chee Lee, Timothy J. Price, Maressa A. Bruhn, Niall C. Tebbutt, Jenny Hardingham
Publikováno v:
Journal of Clinical Oncology. 32:502-502
502 Background: There remains a need for predictive biomarkers in mCRC to better identify patients who clinically benefit from anti-VEGF therapy, in particular bevacizumab (BEV). The AGITG MAX trial compared capecitabine (C) with capecitabine (+/- mi
Autor:
Michitaka Nagase, Mutsumi Fukunaga, Hideyuki Mishima, Keiichiro Ishibashi, Michiya Kobayashi, Toshio Otsuji, Junichi Hasegawa, Junichi Sakamoto, Masaki Matsuoka, Akinori Takagane, Taishi Hata, Yoshinori Munemoto, Koji Oba, Yasuhiro Miyake
Publikováno v:
Journal of Clinical Oncology. 31:502-502
502 Background: Combination chemotherapy of capecitabine plus oxaliplatin (XELOX) with bevacizumab is commonly used as standard chemotherapy for metastatic colorectal cancer (mCRC). A previous meta-analysis showed that there was no difference between
Autor:
Hyung-Jin Kim, In Kyu Lee
Publikováno v:
Journal of Clinical Oncology. 30:502-502
502 Background: This study aimed to establish a correlation between the expression of cathepsin D; p53; Cox-2; EGFR; C-erbB2; Ki-67 protein and the prognosis of colorectal cancer patients. Methods: Tissue samples were collected from 266 patients who
Autor:
S. Srock, Dirk Arnold, Andreas Kutscheidt, Axel Hinke, Manfred Kindler, M. Schulze, Volker Petersen, Joerg Seraphin
Publikováno v:
Journal of Clinical Oncology. 29:502-502
502 Background: As a result of the long PFS with bev-containing combinations in first-line mCRC, discontinuation of at least one CT component after an “induction” period and continuation with “maintenance” Tx is common. It is anticipated that